PTGX Company Profile and Key Details

Q: Who are the executives of PTGX?

Ms. Abha BommireddiExecutive Vice President of Portfolio & Program ManagementDr. Dinesh V. Patel Ph.D.Chief Executive Officer, Pres, Sec. & DirectorMr. Mohammad MasjedizadehExecutive Vice President & Chief Technology OfficerDr. David Y. Liu Ph.D.Chief R&D Strategy OfficerMr. Matthew M. GoslingExecutive Vice President & Gen. CounselDr. Richard S. ShamesClinical AdvisorDr. Suneel K. Gupta Ph.D.Chief Devel. OfficerMr. Asif AliExecutive Vice President & Chief Financial OfficerMr. Mohammad Masjedizadeh Ph.D.Executive Vice President & Chief Technical OfficerDr. Ashok Bhandari Ph.D.Executive Vice President & Chief Drug Discovery and Preclinical Devel. OfficerMs. Carena SpiveySenior Vice President of HRDr. Scott Eric Plevy M.D.Executive Vice President & Therapeutic Head of GastroenterologyDr. Richard S. Shames M.D.Clinical AdvisorMr. Carter J. KingSenior Vice President of Bus. Devel.

NASDAQ : PTGX

Protagonist Therapeutics

$129.89

-1.53-1.16%

At Close 4:00 PM

58.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Protagonist Therapeutics, Inc. (PTGX) stock declined over -1.16%, trading at $129.89 on NASDAQ, down from the previous close of $131.42. The stock opened at $131.36, fluctuating between $125.32 and $131.36 in the recent session.

Stock Snapshot

131.42

Prev. Close

8.35B

Market Cap

125.3225

Day Low

-71.76

P/E Ratio

-1.81

EPS (TTM)

-1.17

Cash Flow per Share

131.36

Open

64.31M

Number of Shares

131.36

Day High

94.41%

Free Float in %

5.58

Book Value

541.01K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	130.05	131.36	125.32	129.89	541.01K
Jul 10, 2026	137.12	137.12	130.64	131.42	937.18K
Jul 09, 2026	139.26	141.10	136.99	137.64	1.17M
Jul 08, 2026	139.50	140.95	136.08	140.07	914.98K
Jul 07, 2026	132.59	141.08	130.69	140.85	1.37M
Jul 06, 2026	131.25	132.79	128.15	131.50	639.78K
Jul 02, 2026	125.89	131.87	125.24	131.62	704.76K
Jul 01, 2026	122.96	126.04	122.48	125.17	496.52K
Jun 30, 2026	122.04	124.72	119.57	122.58	556.98K
Jun 29, 2026	121.34	126.59	118.27	121.63	740.18K
Jun 26, 2026	122.00	123.43	118.31	121.88	2.58M
Jun 25, 2026	122.31	126.25	121.48	122.63	1.04M
Jun 24, 2026	119.38	124.80	118.81	122.15	1.12M
Jun 23, 2026	114.66	119.85	114.56	118.96	661.24K
Jun 22, 2026	113.24	116.57	113.24	115.03	1.19M
Jun 18, 2026	112.88	114.49	111.17	112.86	1.52M
Jun 17, 2026	110.84	113.47	110.11	111.44	685.66K
Jun 16, 2026	112.83	113.66	108.53	110.64	338.75K
Jun 15, 2026	109.10	112.77	109.10	112.46	451.32K
Jun 12, 2026	109.85	111.78	109.60	109.78	447.34K

Contact Details

Newark, CA 94560-1160

United States

https://www.protagonist-inc.com 510 474 0170

About Company

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) closed at $129.89 USD, losing -$1.53 (-1.16%) from the previous close of $131.42. The stock is currently mid-range between its 52-week high and low $50.48 and $141.10. With a market capitalization of about $8.35 billion, Protagonist Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.79). Key stats such as the average daily volume over the past year has been around 722.65 thousand shares, in line with its 52-week average. Headquartered in Newark, CA, Protagonist Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dinesh V. Patel, the company employs approximately 132 people and listed since August 11, 2016. Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 5.63%, SMA50 4.49%, SMA200 28.41%). The stock’s 14-day RSI is 62.45 (firm momentum), while the ATR of 3.54 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.44% below its high and over 153.92% above its low. Average 10-day trading volume of 929.24 thousand shares is slightly above the 3-month average of 705.39 thousand, indicating heightened recent market interest.

Valuation Metrics

Protagonist Therapeutics, Inc. trades at a P/E ratio of -71.54, slightly below the S&P 500 average, with a price-to-sales ratio of 111.94 and a price-to-book ratio of 12.8 reflecting a rich premium to book value. The P/FCF stands at -71.28, also below market averages. Compared to sector medians, Protagonist Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Protagonist Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.13. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of $0.05. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$42.69. Analyst sentiment is bullish. Analyst rating data shows there are 15 Strong Buy ratings, 15 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $145.00 to $69.00. The high target offers 11.63% upside. The low target suggests -46.88% downside. The mean target is $102.58. This offers -21.03% upside. Protagonist Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -107.69%. The prior quarter beat by 30.19%. Over the last six quarters, Apple has recorded several small beats. These include 3200.0% in February 21, 2025.

Shareholding & Insider Activity

Protagonist Therapeutics, Inc. has 62.21 million shares outstanding. The public float is 43.15 million shares, elevated short interest at 11.10% of float. This equals 5.76 million shares. The short ratio is 7.93 days. Institutional investors hold 126.19% of the float. Insiders own 0.71%. Papanek Julie holds 2.45 million shares, JOHNSON & JOHNSON has 2.45 million shares and CANAAN X L.P. has 2.12 million shares. Over the past six months, insider transactions show net selling. They sold 409.64 thousand shares across 23 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Protagonist Therapeutics generated $60.00M in revenue, or $1.06 per share. Gross margin was 94.48%, operating margin -156.09%, and net profit margin -131.59%. Returns are negative, with ROA at -22.06% and ROE at -23.45%.
On valuation metrics, Protagonist Therapeutics trades at a P/E of -71.54, P/S of 111.94 and P/B of 12.80. The current ratio is 17.76 and quick ratio is 17.76. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -7284.84 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -11.93.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Protagonist Therapeutics posted revenue of $60.00M, down slightly from $26.58M in the prior quarter. Gross profit was $56.69M (margin 94.48%). Operating income was - $93.65M (margin -156.1%). Net income was- $78.96M (EPS - $1.39).
The company ended the quarter with $341.62M in cash and short-term investments, a total debt of $1.14M, and net debt of - $185.59M. Total assets were $357.95M, with equity of $336.68M. Financials further reflected weakness, with operating cash flow of - $70.24M, free cash flow of - $70.85M, and capital expenditures of - $609.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Protagonist Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.23%, with price expected at $149.67 by July 27, 2026, within a range of $146.15 to $153.20 3-Month Outlook: Projected rise of 77.34%, reaching $230.35 by October 08, 2026, with a range of $228.49 to $232.87. 1-Year Outlook: Projected gain of 24.72%, with price at $162.00 by July 13, 2027, within a range of $158.33 to $166.79.

Key Takeaways

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shares are flat -4.49% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Protagonist Therapeutics, Inc. trading at a premium to the broader market with a P/E of -71.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $68.31, suggesting -47.41% downside. Our AI forecast model points to short-term strength (15.23% over two weeks), a medium-term rise (77.34% over three months), and a longer-term gain (24.72% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Protagonist Therapeutics, Inc. (PTGX) stock price?

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stock price is $129.89 in the last trading session. During the trading session, PTGX stock reached the peak price of $131.36 while $125.32 was the lowest point it dropped to. The percentage change in PTGX stock occurred in the recent session was -1.16% while the dollar amount for the price change in PTGX stock was - $1.53.

PTGX's industry and sector of operation?

The NASDAQ listed PTGX is part of Biotechnology industry that operates in the broader Healthcare sector. Protagonist Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PTGX?

Ms. Abha Bommireddi
Executive Vice President of Portfolio & Program Management
Dr. Dinesh V. Patel Ph.D.
Chief Executive Officer, Pres, Sec. & Director
Mr. Mohammad Masjedizadeh
Executive Vice President & Chief Technology Officer
Dr. David Y. Liu Ph.D.
Chief R&D Strategy Officer
Mr. Matthew M. Gosling
Executive Vice President & Gen. Counsel
Dr. Richard S. Shames
Clinical Advisor
Dr. Suneel K. Gupta Ph.D.
Chief Devel. Officer
Mr. Asif Ali
Executive Vice President & Chief Financial Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive Vice President & Chief Technical Officer
Dr. Ashok Bhandari Ph.D.
Executive Vice President & Chief Drug Discovery and Preclinical Devel. Officer
Ms. Carena Spivey
Senior Vice President of HR
Dr. Scott Eric Plevy M.D.
Executive Vice President & Therapeutic Head of Gastroenterology
Dr. Richard S. Shames M.D.
Clinical Advisor
Mr. Carter J. King
Senior Vice President of Bus. Devel.

How PTGX did perform over past 52-week?

PTGX's closing price is 157.28% higher than its 52-week low of $50.49 where as its distance from 52-week high of $141.10 is -7.95%.

How many employees does PTGX have?

Number of PTGX employees currently stands at 124.

Link for PTGX official website?

Official Website of PTGX is: https://www.protagonist-inc.com

How do I contact PTGX?

PTGX could be contacted at phone 510 474 0170 and can also be accessed through its website. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, United States.

How many shares of PTGX are traded daily?

PTGX stock volume for the day was 541.01K shares. The average number of PTGX shares traded daily for last 3 months was 722.65K.

What is the market cap of PTGX currently?

The market value of PTGX currently stands at $8.35B with its latest stock price at $129.89 and 64.31M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	124
Beta	1.79
Sales or Revenue	$60.00M
5Y Sales Change%	-0.236%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PTGX Company Profile and Key Details

Protagonist Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways